These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 11795410)

  • 1. DOTS and DOTS-plus: not the only answer.
    Farmer P
    Ann N Y Acad Sci; 2001 Dec; 953():165-84. PubMed ID: 11795410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Directly observed treatment, short-course strategy and multidrug-resistant tuberculosis: are any modifications required?
    Bastian I; Rigouts L; Van Deun A; Portaels F
    Bull World Health Organ; 2000; 78(2):238-51. PubMed ID: 10743297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Multiple drug resistance: a threat for tuberculosis control].
    Cardoso EM
    Rev Panam Salud Publica; 2004 Jul; 16(1):68-73. PubMed ID: 15333267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decline in rates of acquired multidrug-resistant tuberculosis after implementation of the directly observed therapy, short course (DOTS) and DOTS-Plus programmes in Taiwan.
    Chien JY; Lai CC; Tan CK; Chien ST; Yu CJ; Hsueh PR
    J Antimicrob Chemother; 2013 Aug; 68(8):1910-6. PubMed ID: 23580558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of treating multidrug-resistant tuberculosis.
    Resch SC; Salomon JA; Murray M; Weinstein MC
    PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012.
    Chang KC; Yew WW
    Respirology; 2013 Jan; 18(1):8-21. PubMed ID: 22943408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Directly observed therapy, short-course: the best way to prevent multidrug-resistant tuberculosis.
    Yew WW
    Chemotherapy; 1999; 45 Suppl 2():26-33. PubMed ID: 10449895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis.
    Becerra MC; Freeman J; Bayona J; Shin SS; Kim JY; Furin JJ; Werner B; Sloutsky A; Timperi R; Wilson ME; Pagano M; Farmer PE
    Int J Tuberc Lung Dis; 2000 Feb; 4(2):108-14. PubMed ID: 10694087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drug resistant tuberculosis].
    Zwolska Z; Augustynowicz-Kopeć E
    Pol Merkur Lekarski; 2011 May; 30(179):362-6. PubMed ID: 21675144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology of Primary Multidrug-Resistant Tuberculosis, Vladimir Region, Russia.
    Ershova JV; Volchenkov GV; Kaminski DA; Somova TR; Kuznetsova TA; Kaunetis NV; Cegielski JP; Kurbatova EV
    Emerg Infect Dis; 2015 Nov; 21(11):2048-51. PubMed ID: 26488585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies.
    Kibret KT; Moges Y; Memiah P; Biadgilign S
    Infect Dis Poverty; 2017 Jan; 6(1):7. PubMed ID: 28093078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trench warfare in a battle with TB.
    Marshall E
    Science; 2008 Jul; 321(5887):362-4. PubMed ID: 18635790
    [No Abstract]   [Full Text] [Related]  

  • 13. Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current status and future prospects.
    Yew WW
    Kekkaku; 2011 Jan; 86(1):9-16. PubMed ID: 21401001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework.
    Pablos-Mendez A; Gowda DK; Frieden TR
    Bull World Health Organ; 2002; 80(6):489-95; discussion 495-500. PubMed ID: 12132008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-resistant tuberculosis--current dilemmas, unanswered questions, challenges, and priority needs.
    Zumla A; Abubakar I; Raviglione M; Hoelscher M; Ditiu L; McHugh TD; Squire SB; Cox H; Ford N; McNerney R; Marais B; Grobusch M; Lawn SD; Migliori GB; Mwaba P; O'Grady J; Pletschette M; Ramsay A; Chakaya J; Schito M; Swaminathan S; Memish Z; Maeurer M; Atun R
    J Infect Dis; 2012 May; 205 Suppl 2():S228-40. PubMed ID: 22476720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative.
    Nathanson E; Gupta R; Huamani P; Leimane V; Pasechnikov AD; Tupasi TE; Vink K; Jaramillo E; Espinal MA
    Int J Tuberc Lung Dis; 2004 Nov; 8(11):1382-4. PubMed ID: 15581210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of multidrug-resistant tuberculosis: Update 2007.
    Yew WW; Leung CC
    Respirology; 2008 Jan; 13(1):21-46. PubMed ID: 18197909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects.
    Kurbatova EV; Taylor A; Gammino VM; Bayona J; Becerra M; Danilovitz M; Falzon D; Gelmanova I; Keshavjee S; Leimane V; Mitnick CD; Quelapio MI; Riekstina V; Viiklepp P; Zignol M; Cegielski JP
    Tuberculosis (Edinb); 2012 Sep; 92(5):397-403. PubMed ID: 22789497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Drug-resistant pulmonary tuberculosis at the penitentiaries].
    Kononets AS
    Probl Tuberk Bolezn Legk; 2008; (12):60-3. PubMed ID: 19227326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of an effective multidrug-resistant tuberculosis control programme in the setting of an immature HIV epidemic: system dynamics simulation model.
    Atun RA; Lebcir R; Drobniewski F; Coker RJ
    Int J STD AIDS; 2005 Aug; 16(8):560-70. PubMed ID: 16105192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.